FDA approves Lilly and Boehringer's Basaglar insulin glargine product to treat diabetes

The US Food and Drug Administration has granted approval for Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news